McLaren C - Search Results

1

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C. Johnson M, et al. Among authors: mclaren c. AIDS. 2006 Mar 21;20(5):711-8. doi: 10.1097/01.aids.0000216371.76689.63. AIDS. 2006. PMID: 16514301 Clinical Trial.

2

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.

Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C. Mobley JE, et al. Among authors: mclaren c. AIDS. 1999 Jul 30;13(11):F87-93. doi: 10.1097/00002030-199907300-00003. AIDS. 1999. PMID: 10449279 Clinical Trial.

3

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C; BMS AI424-043 Study Group. Cohen C, et al. Among authors: mclaren c. Curr Med Res Opin. 2005 Oct;21(10):1683-92. doi: 10.1185/030079905x65439. Curr Med Res Opin. 2005. PMID: 16238909 Clinical Trial.

4

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Colonno R, et al. Among authors: mclaren c. J Infect Dis. 2004 May 15;189(10):1802-10. doi: 10.1086/386291. Epub 2004 Apr 27. J Infect Dis. 2004. PMID: 15122516

5

Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.

Allan JD, Connolly KJ, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE. Allan JD, et al. Among authors: mclaren c. Clin Infect Dis. 1993 Feb;16 Suppl 1:S46-51. doi: 10.1093/clinids/16.supplement_1.s46. Clin Infect Dis. 1993. PMID: 8425019 Clinical Trial.

6

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS. Japour AJ, et al. Among authors: mclaren c. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46. doi: 10.1097/00042560-199611010-00005. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8898668 Clinical Trial.

7

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: mclaren c. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205

8

Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.

Cooley TP, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, McCaffrey RP, Liebman HA. Cooley TP, et al. Among authors: mclaren c. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S552-60. doi: 10.1093/clinids/12.supplement_5.s552. Rev Infect Dis. 1990. PMID: 1974727

9

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA. Cooley TP, et al. Among authors: mclaren c. N Engl J Med. 1990 May 10;322(19):1340-5. doi: 10.1056/NEJM199005103221902. N Engl J Med. 1990. PMID: 2139174 Free article.

10

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.

Gathe J Jr, Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, McLaren C. Gathe J Jr, et al. Among authors: mclaren c. J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):399-403. doi: 10.1097/00126334-200212010-00005. J Acquir Immune Defic Syndr. 2002. PMID: 12447010 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters